3B BlackBio Dx (BOM:532067) ROCE % : 20.83% (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is 3B BlackBio Dx ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. 3B BlackBio Dx's annualized ROCE % for the quarter that ended in Dec. 2023 was 20.83%.

3B BlackBio Dx ROCE % Historical Data

The historical data trend for 3B BlackBio Dx's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3B BlackBio Dx ROCE % Chart

3B BlackBio Dx Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

31.14

33.20

162.64

26.60

18.93

3B BlackBio Dx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															21.31	16.83	18.43	19.18	20.83

3B BlackBio Dx ROCE % Calculation

3B BlackBio Dx's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	355.079	/	( ( (1920.914 - 169.008)	+	(2140.586 - 141.838) )	/ 2 )
	=	355.079	/	( (1751.906	+	1998.748)	/ 2 )
	=	355.079	/	1875.327
	=	18.93 %

3B BlackBio Dx's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	447.216	/	( ( (2249.207 - 102.059)	+	(0 - 0) )	/ 1 )
	=	447.216	/	( ( 2147.148	+	0 )	/ 1 )
	=	447.216	/	2147.148
	=	20.83 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3B BlackBio Dx (BOM:532067) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

3B BlackBio Dx ROCE % Related Terms

Thank you for viewing the detailed overview of 3B BlackBio Dx's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

3B BlackBio Dx (BOM:532067) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3B BlackBio Dx Ltd (BOM:532067) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

7-C, Industrial Area, Govindpura, Bhopal, MP, IND, 462023

Website

https://www.3bblackbio.com

3B BlackBio Dx Ltd is one of the leading Indian companies in the field of PCR-based Molecular Diagnostic Kits. The Company is ISO 13485:2016 certified, GMP-compliant biotech R&D organization, as an Indo-Spanish JV company and engaged in the design, development, manufacturing and commercialization of PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents.

3B BlackBio Dx (BOM:532067) Headlines

No Headlines